DCPIB

DCPIB is a potent and selective small molecule inhibitor of the volume-regulated anion channel (VRAC), also known as the volume-sensitive outlier-rectifying (VSOR) anion channel. It was originally developed as a derivative of the diuretic ethacrynic acid. DCPIB is widely utilized as a pharmacological tool in neuroscience research to investigate the mechanisms of regulatory volume decrease (RVD) and the release of excitatory neurotransmitters like glutamate from swollen astrocytes. In experimental models of acute ischemic stroke and cytotoxic edema, DCPIB has been shown to mitigate astrocyte swelling, reduce the spatial spread of spreading depolarization (SD), and decrease excitotoxic glutamate accumulation. Although it demonstrates therapeutic potential in preclinical models for limiting secondary brain injury, it is currently primarily available as a research-use-only reagent and has not transitioned into clinical trials.

Other names

4-[(2-Butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]butanoic acid